SPI-1005 Middle dose

DRUG2 trials

Sponsors

Sound Pharmaceuticals, Incorporated

Conditions

Head and Neck CancerHearing LossLung CancerNeuropathyOtotoxicityTemporary Auditory Threshold ShiftTinnitus

Phase 2

Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

CompletedNCT01444846

Sound Pharmaceuticals, IncorporatedTemporary Auditory Threshold Shift

Start: 2011-09-01End: 2014-03-01Updated: 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

WithdrawnNCT01451853

Sound Pharmaceuticals, IncorporatedHead and Neck Cancer, Hearing Loss, Lung Cancer +3

Start: 2026-06-01End: 2026-06-01Updated: 2026-06-03

Related Papers

Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial.

2017-07-14187 citations